The emergence of tumor precedes and contributes toweakening of the immune surveillance of antigenic homeostasis of the body and in the process of tumor growth and often develop mechanisms to ensure the "escape" of tumor cells from surveillance by the immune system. In addition, the function of the immune system additionally have a negative impact stress, anesthesia, surgical trauma, chemotherapy, radiation therapy, age of patients, particularly postoperative period and other factors. All this allows us to conclude that significantly improve the efficiency of the main methods of treatment of cancer pathology is possible with the help of therapy, immunomodulatory drugs.
Despite the difficulties and the presence of yetoutstanding issues, immunotherapy has several advantages over chemotherapy and radiation therapy. This type of treatment effect on tumors cells indirectly - through the activation of the immune system in general, and directly - through the activation of the functions of its killer cells without damaging normal cells. However, the possibility of immunotherapy in oncology may be limited in the case of reducing the immunocompetent patients, as well as the development of immunological tolerance with the progressive growth of tumors, necessitating the removal of the body of the main mass of tumor cells during treatment of patients with complex oncopathology.
Modern radiation therapy and chemotherapy arethe main methods of treatment of cancer patients. In order to increase the effectiveness of anticancer therapy are developed and applied more aggressive schemes of radiation and chemotherapy. However, the intensification of the primary treatment leads to the development of functional and quantitative expressed disorders of the immune system, marketed autoimmune, allergic and infectious complications. Develop complications, in turn, hinder the implementation of basic treatment in the optimal mode, reducing its efficiency and compromising the quality of life of patients
Therefore, at the present stage is given a lot of attention of the immune system of cancer patients, and the use of immunotherapy in the treatment of complex patients
In the treatment of cancer patientsIt is the most appropriate use of immunomodulators - drugs, which at therapeutic doses act primarily on the changed figures, normalizing the basic functions of the immune system
In recent years, the practice of oncologyeffectively used peptide preparation GA-40. Unlike hormones, GA-40 has immunoregulatory action on the immune system cells. The independent nature of the drug produces a definite advantage over the use of hormones and avoids kankroznogo acute inflammation, reduce suppression of tumor immunity. This fact is of exceptional importance in immune in cancer patients. GA-40 has a wide range of regulatory actions and its clinical efficacy is based on the ability to partially or fully recover indicators of T-cell, phagocytic immunity, normalize the production of proinflammatory mediators, providing correction oxidation-antioxidant system and lipid metabolism.
The use of adequate immunotherapyIt contributes to the prevention of postoperative complications of side effects chemoradiotherapy, causing possible to perform complete treatment programs, and improving the quality of life of cancer patients.
A variety of positive clinical andimmunological effects, no contraindications should contribute to a more widespread adoption of these drugs in oncology practice for the correction of immunodeficiency states, leykopoeza stimulation, eliminating the side effects of radiation and chemotherapy, increased PFS and OS cancer patients, improving their quality of life.